SS-31 before NAD+: what the peptide stack evidence actually shows

What did @coachcam.peps3 actually say?

The creator argues that NAD+ supplementation can backfire if your mitochondria are already compromised, specifically because of cardiolipin damage. The logic goes: damaged cardiolipin destabilizes the electron transport chain complexes, causing electrons to "leak out the sides" and react with oxygen to form excess reactive oxygen species (ROS). The proposed fix is SS-31 first, which the creator says stabilizes cardiolipin, restores complex function, and makes subsequent NAD+ supplementation productive rather than counterproductive.

The creator also explains that cytochrome C, normally an electron carrier, shifts to a peroxidase enzyme role when cardiolipin is damaged, creating what they call "a self-perpetuating loop." They refer to SS-31 going into the "inner mitochondrial membrane" (their phrasing was "antimodicondromembrane," which is a phonetic garbling) to stabilize cardiolipin. The core clinical recommendation: use SS-31 before or alongside NAD+ if you suspect mitochondrial dysfunction.

Does the science back this up?

Surprisingly, a fair amount of it does. The cardiolipin-cytochrome C peroxidase mechanism is real, well-documented, and not widely discussed in wellness circles. The argument that flooding a dysfunctional electron transport chain with more substrates could worsen oxidative stress is mechanistically plausible, even if direct human clinical evidence for this specific sequence is thin.

Cardiolipin is a phospholipid almost exclusively found in the inner mitochondrial membrane and is genuinely required for the structural integrity of complexes I through IV (Pfeiffer et al., 2003, Journal of Biological Chemistry). When cardiolipin is oxidized, cytochrome C does shift toward peroxidase activity, which further degrades cardiolipin, as documented in elegant work by Kagan et al. (2005, Nature Chemical Biology). SS-31 (elamipretide) has demonstrated cardiolipin-stabilizing effects in animal models and several small human trials. Szeto et al. (2014, Journal of the American Society of Nephrology) showed SS-31 improved mitochondrial function in ischemia-reperfusion injury by targeting cardiolipin. The NAD+ piece is trickier. The claim that excess NAD+ could worsen ROS generation in a compromised system is mechanistically logical but lacks direct clinical trial support in humans.

What did they get wrong (or right)?

They got the core biochemistry largely right, which is genuinely impressive for a short-form video. The cytochrome C peroxidase shift is real. The cardiolipin-complex stability relationship is real. SS-31's mechanism of action targeting the inner mitochondrial membrane is real.

What they got wrong, or at least oversimplified: the creator says NAD+ "dumps off electrons at Complex I." That is imprecise. NADH donates electrons to Complex I; NAD+ is the oxidized form that accepts electrons from metabolic reactions upstream. Supplementing with NAD+ precursors (like NMN or NR) raises intracellular NAD+, which increases the NADH/NAD+ cycling capacity. It is not directly "dumping electrons" anywhere. This distinction matters because the mechanism of potential harm is different from what the creator describes.

The creator also presents the SS-31 before NAD+ protocol as though it is established clinical guidance. It is not. It is a plausible hypothesis. Human trial data on this specific combination or sequencing is essentially nonexistent. Presenting it as something people "definitely would need" overstates the evidence considerably. The creator says "some people definitely would need to do SS-31 before NAD+" and that confidence is not warranted by the current literature.

What should you actually know?

The underlying science here is legitimate and worth understanding. Cardiolipin health genuinely matters for mitochondrial efficiency. The cytochrome C peroxidase mechanism is a real pathway in mitochondrial dysfunction. SS-31 is one of the more interesting peptides in serious clinical research, with ongoing trials in heart failure, Barth syndrome, and age-related mitochondrial decline. That context matters.

What the creator does not mention: SS-31 (elamipretide) is an investigational compound. It has not been approved by the FDA for any indication. Human trial data is still limited, and most of the impressive results come from animal models or very small human studies. The idea that you can reliably detect your own cardiolipin damage and self-prescribe a mitochondria-targeting peptide based on TikTok content is a significant leap. If you are experiencing persistent fatigue or exercise intolerance, those symptoms warrant a clinical workup, not a peptide stack built on a 90-second social video. The mechanism the creator describes is real; the jump from mechanism to personal protocol is not supported by evidence.